Innovative Non-antibiotic Strategies for Combating Methicillin-Resistant Staphylococcus aureus in Diabetic Foot
Mohsen Nazari1, Ali Bahrami2, Faezeh Jahanian3
1Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. mohsennazari911@gmail.com.
Abstract:
Diabetic foot infections (DFIs) are a common and serious complication of diabetes mellitus (DM), often caused by methicillin-resistant Staphylococcus aureus (MRSA), which is challenging to treat due to its antibiotic resistance. The ability of MRSA to form biofilms and its resistance to commonly used antibiotics, such as beta-lactams, clindamycin, and trimethoprim-sulfamethoxazole, complicate treatment strategies. The pathophysiology of MRSA in DFIs involves bacterial virulence factors, including adhesion proteins, exotoxins, and immune evasion mechanisms, which allow MRSA to persist in infected wounds despite compromised immune responses in diabetic patients. Diabetes-related conditions such as neuropathy, poor glycemic control, and ischemia further exacerbate the susceptibility to and severity of these infections. With conventional antibiotic therapies facing increasing resistance, alternative non-antibiotic treatment options, including antimicrobial peptides, bacteriophage therapy, and nanotechnology-based interventions, are emerging as promising strategies. This review evaluates these alternative approaches, examining their potential to improve patient outcomes and combat antibiotic-resistant MRSA in DFIs.
Insights
Diabetic foot infections caused by antibiotic-resistant MRSA are difficult to treat. This review explores promising alternative therapies like antimicrobial peptides and bacteriophages to combat these challenging infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Diabetology
Background:
- Diabetic foot infections (DFIs) are a severe complication of diabetes mellitus (DM).
- Methicillin-resistant Staphylococcus aureus (MRSA) is a common pathogen in DFIs, exhibiting resistance to multiple antibiotics.
- MRSA's ability to form biofilms and evade immune responses complicates treatment.
Purpose of the Study:
- To review alternative, non-antibiotic treatment strategies for MRSA in DFIs.
- To evaluate the potential of emerging therapies to overcome antibiotic resistance.
- To discuss the mechanisms of MRSA pathogenesis in the context of diabetic complications.
Main Methods:
- Literature review of current research on DFIs and MRSA.
- Analysis of alternative therapeutic approaches, including antimicrobial peptides, bacteriophage therapy, and nanotechnology.
- Evaluation of the efficacy and mechanisms of these novel treatments.
Main Results:
- Conventional antibiotics are increasingly ineffective against MRSA in DFIs.
- Antimicrobial peptides, bacteriophage therapy, and nanotechnology show promise in combating resistant MRSA.
- These alternative strategies offer potential for improved treatment outcomes.
Conclusions:
- Novel therapeutic strategies are crucial for managing antibiotic-resistant MRSA in DFIs.
- Antimicrobial peptides, bacteriophages, and nanotechnology represent promising avenues for future treatment.
- Further research is needed to translate these findings into clinical practice for diabetic patients.
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:28Acute Pyelonephritis II: Diagnostic Studies and Management